VCL and breast cancer: Simultaneously, DEHP has been reported to not only mediate drug resistance by activating the vinculin/aryl hydrocarbon receptor (AhR)/ERK signaling pathway but also enhance susceptibility to breast cancer by upregulating the Esr1/HDAC6 pathway in female rats [22, 35].